Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector.  MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you elaborate on the status and […]